Introduction
The usual treatment for phimosis is circumcision, which forms a significant paediatric surgical workload. We have evaluated the outcome of topical betamethasone in treating phimosis and its effect on our circumcision rates.
Patients and Methods
In a prospective design, 66 consecutive boys with phimosis were treated with topical 0.05% betamethasone ointment twice daily for 1 month. Phimosis was graded from 1 (no retractibility) to 6 (full and free retraction). Patients who did not achieve full foreskin retraction were treated for a further month and reviewed 6 months after presentation. Patients with scarred foreskin and balanitis xerotica obliterans (BXO) were excluded. The number of circumcisions carried out for 1 year before steroid treatment was compared to that performed during the subsequent year.
Results
A total of 66 boys, aged 1–13 years (median, 5 years) entered the study. At entry, the median grade of phimosis was 2 (IQ range 2–3). After 1 month, the median grade had improved to 5 (IQ range 4–6) and after 6 months it was 6 (IQ range 5–6). On an intention-to-treat basis, 48 boys (73%) had their phimosis cured by betamethasone. Thirteen patients required surgery and 4 were lost to follow-up. During the year before our practice changed, 48 circumcisions were performed compared to 29 in the following year – a reduction of 40%.
Conclusions
Betamethasone reduced the circumcision workload by 40%. We suggest that topical steroid should be the first line of treatment for non-scarred phimosis.
